Overview

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Status:
Not yet recruiting

Trial end date:
2026-05-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).

Phase:

Phase 4

Details

Lead Sponsor:

United Therapeutics

Collaborator:

Lung Biotechnology PBC

Treatments:

Treprostinil